Streetbeat News

Price Targets

AQN

RBC Capital analyst Nelson Ng has reiterated a Sector Perform rating for Algonquin Power (NYSE:AQN) and maintained a price target of $6.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:35 pm

EXEL

Morgan Stanley has maintained an Equal-Weight rating on Exelixis (NASDAQ:EXEL) while raising the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:35 pm

AESI

RBC Capital analyst Keith Mackey maintains an Outperform rating on Atlas Energy Solutions (NYSE:AESI) but lowers the price target from $26 to $25.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:33 pm

IMCR

Morgan Stanley analyst Andrew Galler maintains an Overweight rating on Immunocore Holdings (NASDAQ:IMCR) but lowers the price target from $80 to $74.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:31 pm

ITCI

Morgan Stanley has maintained its Overweight rating on Intra-Cellular Therapies and raised the price target from $92 to $95, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:30 pm

GENI

Benchmark analyst Mike Hickey has reiterated a Buy rating on Genius Sports (NYSE:GENI) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:29 pm

PTCT

Morgan Stanley analyst Jeffrey Hung maintains an Equal-Weight rating on PTC Therapeutics and raises the price target from $32 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:26 pm

MNPR

Monopar Therapeutics shares rose following Rodman & Renshaw's initiation of coverage with a Buy rating and a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:25 pm

FOLD

Morgan Stanley analyst Jeffrey Hung maintains an Overweight rating on Amicus Therapeutics but lowers the price target from $19 to $18.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 4:23 pm